Prener Anne — SEC insider filings
SEC reporting owner CIK 1797917. 12 insider filings on record with FilingPulse; latest filed 2026-11-19.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2021-01-08 to 2026-11-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 2 filings — 1,149 shares, $11,849 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
- Largest priced transaction: sale of 574 shares @ $9.79 ($5,619) in Keros Therapeutics, Inc., filed 2026-11-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | Director | 3 | — | 3 legs · 1,149 sh · $11,849 | 2 |
| Galecto, Inc. (GLTO) | Director | 6 | — | — | 7 |
| Rubius Therapeutics, Inc. (RUBY) | Director | 2 | — | — | 2 |
| Kaleido Biosciences, Inc. (KLDO) | Director | 1 | — | — | 1 |
Insider filings — Prener Anne
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | Keros Therapeutics, Inc. (KROS) | Sale (S): 433 @ $10.77 · Sale (S): 142 @ $11.03 | EDGAR |
| 2026-11-16 | 4 | Keros Therapeutics, Inc. (KROS) | Sale (S): 574 @ $9.79 | EDGAR |
| 2026-07-06 | 4 | Keros Therapeutics, Inc. (KROS) | Grant/award (A): 13,786 @ $0 · Grant/award (A): 14,870 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Galecto, Inc. (GLTO) | Grant/award (A): 720 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Galecto, Inc. (GLTO) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Galecto, Inc. (GLTO) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-15 | 4 | Galecto, Inc. (GLTO) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-05-13 | 4 | Rubius Therapeutics, Inc. (RUBY) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-07-01 | 4 | Kaleido Biosciences, Inc. (KLDO) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-05-28 | 4 | Galecto, Inc. (GLTO) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | Rubius Therapeutics, Inc. (RUBY) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-01-08 | 4 | Galecto, Inc. (GLTO) | Grant/award (A): 18,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1797917 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs